Abstract
In order for the promise of personalised medicine to be realized, a thorough understanding and description of the genetic variants that affect drugs side effects and therapeutic response must be realized for all populations in the world. Although certain populations can have the patterns of genetic variation imputed or extrapolated from other related populations, African populations are too heterogeneous to extrapolate genetic information from one population to the other without missing additional variants of pharmacogenetics relevance. In these early days of 2012, Africa has become the ‘epicenter’ of genomics research investments with the Human Heredity and Health in Africa (H3Africa) Initiative that is accelerating the study of genomics and environmental determinants of common diseases in the African continent. This paper focuses on the status of genomics/pharmacogenomics research in Malawi. The Republic of Malawi is located in Southeast of Africa and its population is made up of eight major native ethnic groups (Chewa or Nyanja, Tumbuka, Yao, Lhomwe, Sena, Tonga, Ngoni and Ngonde) as well as Asians and Europeans. We herein identify a series of gene-centric knowledge gaps that need to be addressed urgently to advance population pharmacogenomics in Malawi. We also underscore the need for research attention and investment in personalized genomics for this African country. The genetic data obtained from the few previous studies show that frequencies of polymorphism in different genes among Malawians are not similar to other African populations, indicating again the need for population specific genomics research across Africa, if the goal of global personalized medicine is going to be achieved equitably for all populations of the world.
Keywords: Bantu population, cancer, global genomics, HIV/AIDS, Malawi, malaria, pharmacogenetics, Southern Africa
Current Pharmacogenomics and Personalized Medicine
Title:Pharmacogenetics Research Developments in Africa: A Focus on Malawi
Volume: 10
Author(s): Elizabeth Kampira, Johnstone Kumwenda, Joep J. van Oosterhout, Mas Chaponda and Collet Dandara
Affiliation:
Keywords: Bantu population, cancer, global genomics, HIV/AIDS, Malawi, malaria, pharmacogenetics, Southern Africa
Abstract: In order for the promise of personalised medicine to be realized, a thorough understanding and description of the genetic variants that affect drugs side effects and therapeutic response must be realized for all populations in the world. Although certain populations can have the patterns of genetic variation imputed or extrapolated from other related populations, African populations are too heterogeneous to extrapolate genetic information from one population to the other without missing additional variants of pharmacogenetics relevance. In these early days of 2012, Africa has become the ‘epicenter’ of genomics research investments with the Human Heredity and Health in Africa (H3Africa) Initiative that is accelerating the study of genomics and environmental determinants of common diseases in the African continent. This paper focuses on the status of genomics/pharmacogenomics research in Malawi. The Republic of Malawi is located in Southeast of Africa and its population is made up of eight major native ethnic groups (Chewa or Nyanja, Tumbuka, Yao, Lhomwe, Sena, Tonga, Ngoni and Ngonde) as well as Asians and Europeans. We herein identify a series of gene-centric knowledge gaps that need to be addressed urgently to advance population pharmacogenomics in Malawi. We also underscore the need for research attention and investment in personalized genomics for this African country. The genetic data obtained from the few previous studies show that frequencies of polymorphism in different genes among Malawians are not similar to other African populations, indicating again the need for population specific genomics research across Africa, if the goal of global personalized medicine is going to be achieved equitably for all populations of the world.
Export Options
About this article
Cite this article as:
Kampira Elizabeth, Kumwenda Johnstone, J. van Oosterhout Joep, Chaponda Mas and Dandara Collet, Pharmacogenetics Research Developments in Africa: A Focus on Malawi, Current Pharmacogenomics and Personalized Medicine 2012; 10 (1) . https://dx.doi.org/10.2174/1875692111201010087
DOI https://dx.doi.org/10.2174/1875692111201010087 |
Print ISSN 1875-6921 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6913 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats
Current Alzheimer Research Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs
Current Pharmaceutical Design Diabetes and Vascular Disease: Basic Concepts of Nitric Oxide Physiology, Endothelial Dysfunction, Oxidative Stress and Therapeutic Possibilities
Current Vascular Pharmacology Chimeric Antigen Receptors; Their Current and Futuristic Scope
Current Signal Transduction Therapy Reproductive Toxicity of T Cells in Early Life: Abnormal Immune Development and Postnatal Diseases
Current Drug Targets Botanical Therapeutics (Part II): Antimicrobial and In Vitro Anticancer Activity against MCF7 Human Breast Cancer Cells of Chamomile, Parsley and Celery Alcoholic Extracts
Anti-Cancer Agents in Medicinal Chemistry Withdrawal Notice: Role, Significance and Association of microRNA-10a/b in Physiology of Cancer
MicroRNA RBM15 Functions in Blood Diseases
Current Cancer Drug Targets The Psychopharmacology of Appetite: Targets for Potential Anti-Obesity Agents
Current Medicinal Chemistry - Central Nervous System Agents Low Radiation Dose with Triple-Rule-Out CT Angiography in Diagnosis of Acute Chest Pain
Current Medical Imaging Association of Hypothyroidism with Body Mass Index, Systolic Blood Pressure and Proteinuria in Diabetic Patients: Does treated Hypothyroidism with Thyroxine Replacement Therapy Prevent Nephropathy/Chronic Renal Disease?
Current Diabetes Reviews Expression of Angiogenesis-related Genes in a Group of Iranian Cases of Breast Cancer
Current Pharmacogenomics and Personalized Medicine Targeting CD4 to Disrupt Signaling Through Membrane Rafts: Towards a Raft-Based Therapeutics
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Therapeutic Exploitation of Apoptosis and Autophagy for Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Drug-Resistance in Central Nervous System Tumors: From the Traditional Cell-Resistance Model to the Genetically Driven Approaches on Therapy
Current Pharmaceutical Biotechnology Heparanase Patents: Dim Past and Bright Future
Recent Patents on Inflammation & Allergy Drug Discovery Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Current Cancer Drug Targets Antipsoriatic Drug Development: Challenges and New Emerging Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Early Life Vitamin D Status and Lung Development
Current Respiratory Medicine Reviews